There is an annual increase in patients with metastatic liver disease. In half of patients, the disease is revealed in the late stages, which significantly reduces the possibility of treatment. Laser ablation is the new promising method for providing local destruction. The purpose of our investigation is to increase the effectiveness of treatment of patients with metastatic liver disease.  In this research we analyzed treatment results of 27 patients with metastatic liver lesions who underwent laser ablation for the period from March 2017 to March 2023. The size of formations was from 10 - 40 mm, average size 29,8 ± 1,7 mm. Laser destruction was performed under general anesthesia as following type:  percutaneous, laparoscopic or open access under ultrasound examination in real time mode. The size of the liver tumor determined the number of installed working light guides, localization in the liver determined the depth of insertion of the guiding needles. Ultrasound, MRI and CT with intravenous contrast were used for the dynamically control of ablation effectiveness. In early postoperative period were noticed 3-days pain syndrome (which could be corrected by the painkillers) and 10-days changing of biochemical analyses (ALT, AST, Alk. phos). One subcapsular hematoma in the area of light guide facility was revealed. It didn’t require for surgery intervention. Average bed day stood at 4 days. Оne-year overall survival stood at 88%, two-year overall survival stood at 2-years stood at 71%, 3-уеars stood 43,5%. Laser ablation allows both expanding the indications for surgical treatment of patients with metastatic liver lesion and performing tumor destruction. Also it can be reserved for patients having varies contraindications for radical operation (including functional liver insufficient volume) of due to the minimal invasiveness and low trauma.

Mikhail Trandofilov completed his PhD at the age of 27 years from Rostov Medical University, Russia. He is the head of the department of the first surgery department of the University Clinic of ROSUNIMED. He has over 50 publications that have been cited over 20 times, and his publication h-index is 2.